锁定二聚化CXCL12在头颈癌中发挥放疗增敏效应
本研究评估工程化单体与二聚化CXCL12变体(CXCL121与CXCL122)在头颈鳞状细胞癌(HNSCC)中的治疗潜力及与放疗联用的叠加效应;CXCL122显著抑制HNSCC细胞增殖并增强放疗效果,机制可能涉及CXCR4受体的偏向性激动及KISS1R通路上调;体内实验中CXCL122定位于肿瘤部位并增强放疗抑制肿瘤生长的作用。
要点
- CXCL122显著降低HNSCC细胞增殖并增强放疗效果。
- 机制可能涉及CXCR4受体偏向性激动及KISS1R通路上调。
- 体内CXCL122定位于肿瘤并增强放疗抑制肿瘤生长。
核心结论
- CXCL122联合放疗在HNSCC中显示出强效抗肿瘤作用,这些发现支持进一步临床研究CXCL122以增强放疗效果。
研究设计与样本
- 评估临床HNSCC活检组织(既往未治疗与放疗后复发疾病)中CXCR4的表达。
- 用CXCL12变体与放疗联合处理HNSCC细胞系,检测增殖、基因表达变化及分子机制。
- 体内研究评估工程化CXCL12的生物分布,并在人源化细胞系来源异种移植(CDX)模型中测试这些治疗。
主要发现
- CXCL122显著降低HNSCC细胞增殖并增强放疗效果,可能通过CXCR4受体的偏向性激动及KISS1R通路上调实现。
- 体内实验中,CXCL122定位于肿瘤部位并增强放疗抑制肿瘤生长的作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) presents significant treatment challenges, particularly in cases unrelated to human papillomavirus (HPV). The chemokine receptor CXCR4, interacting with its ligand CXCL12, plays a crucial role in tumor proliferation, metastasis, and treatment resistance. This study explores the therapeutic potential of engineered monomeric and dimerized CXCL12 variants (CXCL121 and CXCL122, respectively) in HNSCC and evaluates potential additive effects when combined with radiation therapy. METHODS: Clinical HNSCC biopsies were evaluated for CXCR4 expression in both previously untreated and radiorecurrent disease. HNSCC cell lines were then treated with combinations of CXCL12 variants and radiotherapy and interrogated for proliferation, gene expression change, and underlying molecular mechanisms. In vivo studies evaluated the biodistribution of engineered CXCL12 and tested these treatments in humanized cell line-derived xenograft (CDX) models. RESULTS: CXCL122 significantly reduced HNSCC cell proliferation and enhanced the effects of radiotherapy, likely through biased agonism at the CXCR4 receptor and upregulation of the KISS1R pathway. In vivo, CXCL122 localized to tumor sites and augmented the effects of radiation to inhibit tumor growth. CONCLUSIONS: CXCL122, in combination with radiation, demonstrates potent anti-tumor effects in HNSCC. These findings support further clinical investigation of CXCL122 to enhance the effects of radiotherapy.
引用
- Espinosa OV, Awan M, Memon AA, et al. Locked Dimerized CXCL12 Exerts Radiosensitizing Effects in Head and Neck Cancer. Head Neck. 2024. PMID: 39722591. doi:10.1002/hed.28048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。